ArticleMedecine tropicale et sante internationale2024
[Thyrotoxic hypokalemic periodic paralysis in a black African man in Abidjan (Côte d'Ivoire)].
Article in Medecine tropicale et sante internationale, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Thyrotoxic hypokalemic periodic paralysis (THPP) is a sporadic form of hypokalemic periodic paralysis (HPP). It is a diagnostic and therapeutic emergency rarely described in the black population. We report a case in a black subject from Côte d'Ivoire. Clinical case: Mr. NK, 37 years old, was admitted to hospital with rapidly progressive motor deficit in all four limbs. The patient had hyperthyroidism, which was treated with neomercazole. His medical history revealed an initial episode that resolved within 30 minutes, followed by a more severe recurrence 4 months later, associated with discontinuation of treatment. Clinical examination revealed flaccid tetraparesis mainly affecting the lower limbs. Biological tests showed hypokalemia of 2.6 mEq/L, ultrasensitive TSH was low (less than 0.005 µL/mL) with T3 and T4 elevations of 24.42 µL/mL and 79.68 µL/mL respectively. We have retained the diagnosis of THPP. The clinical course was satisfactory after correction of the kalemia and readjustment of the hyperthyroidism treatment. Discussion: THPP is common in young Asians and rare in black Africans. The duration of paralysis varies from 1 to 72 hours, with an average of almost 24 hours. Respiratory paralysis, which is potentially serious, is rare. However, discontinuation of treatment in patients already on the drug may predispose to paralysis. Conclusion: The favorable evolution of paralysis after correction of kalemia was confirmed. Our observation highlights the importance of maintaining good thyroid function in patients monitored for hyperthyroidism.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.